Status:
RECRUITING
Study to Learn More About Safety of Aflibercept Injection in Japanese Patients With Neovascular Glaucoma (NVG)
Lead Sponsor:
Bayer
Conditions:
Neovascular Glaucoma
Eligibility:
All Genders
Brief Summary
This is a prospective, observational, multi-center and post-authorization safety study that includes patients with a diagnosis of Neovascular Glaucoma. The investigator will have made the decision to ...
Eligibility Criteria
Inclusion
- Diagnosis of NVG
- Patients who have received IVT-AFL treatment according to Japanese labeling.
Exclusion
- Patients who are contraindicated based on approved label
- Diagnosis of other indication
Key Trial Info
Start Date :
November 27 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 30 2028
Estimated Enrollment :
480 Patients enrolled
Trial Details
Trial ID
NCT04519619
Start Date
November 27 2020
End Date
June 30 2028
Last Update
January 5 2026
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Many locations
Multiple Locations, Japan